HDAC2 and neoplasm: Patients with a higher percentage of tumor cells positively immune-stained for HDAC1 and HDAC2 expressions were more likely to experience shorter disease-free survival, as well as higher T and N stages, and triple-negative pathology (Fig. 1C, D, S3A, B).